Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy

Annals of Pharmacotherapy

Volumn 49, Issue 10, 2015, Pages 1113-1119

  Knoderer, Chad A ^a   Gritzman, Allison L ^a   Nichols, Kristen R ^a,b,c   Wilson, Amy C ^c  

^a BUTLER UNIVERSITY   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nephrotoxicity; Pediatrics; Pharmacodynamics; Pharmacokinetics; Vancomycin

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN; AMPHOTERICIN B DEOXYCHOLATE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IODINATED CONTRAST MEDIUM; MEROPENEM; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN PLUS TAZOBACTAM; TACROLIMUS; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY WEIGHT; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAM POSITIVE INFECTION; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; YOUNG ADULT; ACUTE KIDNEY INJURY; AGE; CHEMICALLY INDUCED; DRUG COMBINATION; HOSPITAL PATIENT; INCIDENCE; TIME;

ACUTE KIDNEY INJURY; ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; INFANT; INPATIENTS; MALE; TIME FACTORS; VANCOMYCIN;

EID: 84952776107     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015594190     Document Type: Article

References (23)

1. Rybak MJ, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
2. Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther. 2012;34:149-157.
3. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med. 2006;166:2138-2144.
4. Pritchard L, Baker C, Legget J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123: 1143-1149.
5. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55:5475-5479.
6. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29:1107-1115.
7. Knoderer CA, Nichols KR, Lyon KC, Veverka MM, Wilson AC. Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children [published online November 11, 2013]? J Pediatr Infect Dis. doi:10. 1093/jpids/pit076.
8. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-426.
9. Sinclair EA, Yenokyan G, McMunn A, Fadrowski JJ, Milstone AM, Lee CK. Factors associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother. 2014;48:1555-1562.
10. Totapally BR, Machado J, Lee H, Paredes A, Rasynski A. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33:598-602.
11. Cies JJ, Shankar V. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit. Pharmacotherapy. 2013;33:392-400.
12. Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy. 2014;34:1259-1268.
13. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398-402.
14. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospital wide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011;31:871-876.
15. Eiland LS, English TM, Eiland EH. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582-589.
16. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028-1035.
17. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32:e155-e163.
18. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin- resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077-1079. doi:10. 1097/INF. 0b013e318299f75c.
19. Le J, Ngu B, Bradley JS, et al. Vancomycin monitoring in children using Bayesian estimation. Ther Drug Monit. 2014;36:510-518.
20. Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol. 2008;23:2159-2173.
21. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34:670-676.
22. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34:662-669.
23. Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatr Blood Cancer. 2010;55:655-661.